Quick RedHill/IntelGenx FDA response fails to impress investors
This article was originally published in Scrip
Executive Summary
The relatively quick response by RedHill Biopharma and its partner IntelGenx to the FDA's 4 February complete response letter (CRL) for the companies' new drug application (NDA) for RHB-103, an oral thin film formulation of rizatriptan benzoate, a 5-HT1 agonist, which is under investigation as a treatment for acute migraines, did little to stir excitement among investors on 3 March.